Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2024-11-19 Proxy Solicitation & In…
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of Postal Ballot dated November 19, 2024, issued by Valiant Laboratories Limited. It references Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and Sections 108 and 110 of the Companies Act, 2013, which govern shareholder voting procedures. The notice details resolutions to be approved by members through electronic voting, including an increase in authorized share capital and appointment of a new independent director. It includes procedural information about e-voting, cut-off dates, and the role of the scrutinizer. The document is not a report of voting results but a notice seeking shareholder approval via postal ballot. It is not an announcement of results or a report publication but a solicitation for votes. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions.
2024-11-19 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the newspaper publication of the company's audited financial results for the quarter ended September 30, 2024. It references compliance with SEBI (LODR) Regulations and mentions that the financial results were published in newspapers and are available on the company's website. The document itself does not contain the financial results or detailed financial data but is an announcement about the publication of these results. The document length is short (1571 characters), and it serves as a notification rather than the report itself. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-11-14 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement submitted to stock exchanges (BSE and NSE) regarding the utilization of IPO proceeds for the quarter ended September 30, 2024. It references Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of deviations or variations in the use of funds raised through public issues. The document confirms no deviation or variation in fund utilization and includes details about the monitoring agency's confirmation. The document length is 3970 characters, which is relatively short and primarily serves as a compliance disclosure rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis but is a regulatory compliance filing about fund usage. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement and does not constitute a full financial report or other specific report types.
2024-11-13 English
Monitoring Agency Report
Regulatory Filings Classification · 95% confidence The document is a Monitoring Agency Report issued by CARE Ratings Limited for the quarter ended September 30, 2024, related to the utilization of IPO proceeds of Valiant Laboratories Limited. It references SEBI regulations and details the use of funds raised through the IPO, including certifications and comments from the Board of Directors. The report contains substantive financial and operational data about the IPO proceeds utilization and compliance with regulatory requirements. It is not an announcement of a report but the report itself, and it is not a general regulatory filing or certification. This type of report is specific to monitoring the use of IPO proceeds and is distinct from annual reports, audit reports, or earnings releases. Given the nature and content, the best fitting category is Regulatory Filings (RNS) as it is a regulatory compliance report under SEBI regulations but does not fit into other more specific categories like Annual Report or Audit Report. However, since it is a Monitoring Agency Report pursuant to SEBI Listing Obligations and Disclosure Requirements, it is best classified under Regulatory Filings (RNS) as a compliance document rather than a financial report type.
2024-11-13 English
Appointment
Regulatory Filings
2024-11-12 English
Resignation
Regulatory Filings
2024-11-12 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.